Burgdorf – Ypsomed has entered into an exclusive agreement to supply Indian pharmaceutical major Lupin Limited (Lupin) with its reusable and affordable YpsoPen. The YpsoPen would be used to administer Lupin's insulin.
As the third-largest Indian pharmaceutical company with strong growth and over 45 years of market experience, Lupin is intimately acquainted with the Indian market and the needs of patients with diabetes in India. As such, Lupin is an ideal strategic partner for the Swiss injection system manufacturer Ypsomed.
After a transitional period of several months, the titles of the Ypsomed Holding AG will again be included in the SPI starting 12 May 2015. The SPI is the broad market index for the Swiss equity market. In addition to the Swiss Market Index, the SPI is Switzerland's most closely observed stock market index and contains virtually all of the shares traded on the SIX Swiss Exchange from companies based in Switzerland or the Principality of Liechtenstein.
As the third-largest Indian pharmaceutical company with strong growth and over 45 years of market experience, Lupin is intimately acquainted with the Indian market and the needs of patients with diabetes in India. As such, Lupin is an ideal strategic partner for the Swiss injection system manufacturer Ypsomed. According to current estimates by the International Diabetes Federation (IDF), over 65 million people in India have diabetes. By 2030, the number is even expected to increase to over 100 million.
Ypsomed, for its part, is very pleased to be expanding the relationship with the Indian pharmaceutical company, since Lupin has once again selected an injection system from Ypsomed. Ypsomed has been supplying ServoPen, Ypsomed’s spring driven high-end injection pen, to Lupin since 2013.
